Market Cap 348.92M
Revenue (ttm) 0.00
Net Income (ttm) -158.35M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 197,700
Avg Vol 308,558
Day's Range N/A - N/A
Shares Out 80.03M
Stochastic %K 78%
Beta 0.32
Analysts Sell
Price Target $8.00

Company Profile

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection....

Industry: Biotechnology
Sector: Healthcare
Phone: 857 284 8891
Address:
225 Franklin Street, Suite 2100, Boston, United States
DARKP00L
DARKP00L May. 27 at 11:11 AM
$AVIR 07:09 on May. 27 2026 Atea Pharmaceuticals' BEM/RZR Phase 1 Results Show Low Drug-Drug Interaction Risk With Commonly Used Medications For Hepatitis C Patients #tradeideas
0 · Reply
OnlyFibs
OnlyFibs May. 23 at 4:29 PM
Is $AVIR the ultimate binary value play? 🚀 Revenue is non-existent as they fund Phase 3 trials, but the $256M cash pile provides enough runway to get to the 2026 data milestones without dilution. The market is skeptical, but the HCV market is massive. This is a pure clinical-outcome trade—either you believe the data, or you don't. 💎 🐂 Bulls: Look for a sustained close over 4.80 to validate the breakout and trigger the next leg 🐻 Bears: Watch 3.60 for a support test; failure here confirms the bearish trend #avir #Investing #Biotech #hovdid
0 · Reply
rao4
rao4 May. 18 at 9:44 PM
$AVIR why can't just merck take the initiative and buy the company, they have licensed ruzasvir already. Probability of phase 3 hcv being successful is very high if they showed good results in phase 2.
0 · Reply
laaarsas
laaarsas May. 15 at 3:45 PM
$AVIR Ok srsly data leak or what?
0 · Reply
laaarsas
laaarsas May. 14 at 9:52 PM
$AVIR So why is it actually down?
0 · Reply
Following_the_trend
Following_the_trend May. 14 at 2:09 PM
$AVIR Probably should have timed my entry better (3 day rule). Just a starter so no big deal. GL everyone.
0 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor May. 13 at 3:21 PM
$AVIR why the dip today?
1 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor May. 13 at 3:03 PM
$AVIR why the drop today?
0 · Reply
laaarsas
laaarsas May. 13 at 2:41 PM
$AVIR why down today? Unclear to me
1 · Reply
Following_the_trend
Following_the_trend May. 13 at 2:24 PM
$AVIR Ok, finally a starter here.
0 · Reply
Latest News on AVIR
Atea Pharmaceuticals Earnings Call Transcript: Q1 2026

May 12, 2026, 4:30 PM EDT - 4 weeks ago

Atea Pharmaceuticals Earnings Call Transcript: Q1 2026


Atea Pharmaceuticals Slides: Q1 2026

May 12, 2026, 4:30 PM EDT - 4 weeks ago

Atea Pharmaceuticals Slides: Q1 2026


Atea Pharmaceuticals Earnings release: Q1 2026

May 12, 2026, 4:30 PM EDT - 4 weeks ago

Atea Pharmaceuticals Earnings release: Q1 2026


Atea Pharmaceuticals Quarterly report: Q1 2026

May 12, 2026, 4:30 PM EDT - 4 weeks ago

Atea Pharmaceuticals Quarterly report: Q1 2026


Atea Pharmaceuticals Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 6 weeks ago

Atea Pharmaceuticals Proxy statement: Proxy filing


Atea Pharmaceuticals Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 6 weeks ago

Atea Pharmaceuticals Proxy statement: Proxy filing


Atea Pharmaceuticals Earnings Call Transcript: Q4 2025

Mar 5, 2026, 4:30 PM EST - 3 months ago

Atea Pharmaceuticals Earnings Call Transcript: Q4 2025


Atea Pharmaceuticals Annual report: Q4 2025

Mar 5, 2026, 4:30 PM EST - 3 months ago

Atea Pharmaceuticals Annual report: Q4 2025


Atea Pharmaceuticals Earnings release: Q4 2025

Mar 5, 2026, 4:30 PM EST - 3 months ago

Atea Pharmaceuticals Earnings release: Q4 2025


Atea Pharmaceuticals Slides: Q4 2025

Mar 5, 2026, 4:30 PM EST - 3 months ago

Atea Pharmaceuticals Slides: Q4 2025


Atea Pharmaceuticals presents preclinical results of AT-587

2026-02-24T12:40:00.000Z - 3 months ago

Atea Pharmaceuticals presents preclinical results of AT-587


Atea Pharmaceuticals to highlight strategic priorities for FY26

2026-01-08T12:17:39.000Z - 5 months ago

Atea Pharmaceuticals to highlight strategic priorities for FY26


Atea Pharmaceuticals Transcript: Status Update

Nov 13, 2025, 10:00 AM EST - 7 months ago

Atea Pharmaceuticals Transcript: Status Update


Atea Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 12, 2025, 4:30 PM EST - 7 months ago

Atea Pharmaceuticals Earnings Call Transcript: Q3 2025


Atea Pharmaceuticals Quarterly report: Q3 2025

Nov 12, 2025, 4:30 PM EST - 7 months ago

Atea Pharmaceuticals Quarterly report: Q3 2025


Atea Pharmaceuticals Earnings release: Q3 2025

Nov 12, 2025, 4:30 PM EST - 7 months ago

Atea Pharmaceuticals Earnings release: Q3 2025


Atea Pharmaceuticals Slides: Q3 2025

Nov 12, 2025, 4:30 PM EST - 7 months ago

Atea Pharmaceuticals Slides: Q3 2025


Atea Pharmaceuticals announces presentation of data on BEM, RZR

2025-11-07T13:10:51.000Z - 7 months ago

Atea Pharmaceuticals announces presentation of data on BEM, RZR


Atea Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 11 months ago

Atea Pharmaceuticals Earnings Call Transcript: Q2 2025


Atea Pharmaceuticals Quarterly report: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 11 months ago

Atea Pharmaceuticals Quarterly report: Q2 2025


Atea Pharmaceuticals Earnings release: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 11 months ago

Atea Pharmaceuticals Earnings release: Q2 2025


Atea Pharmaceuticals Slides: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 11 months ago

Atea Pharmaceuticals Slides: Q2 2025


Atea Pharmaceuticals Transcript: Status Update

May 14, 2025, 10:00 AM EDT - 1 year ago

Atea Pharmaceuticals Transcript: Status Update


Atea Pharmaceuticals Quarterly report: Q1 2025

May 12, 2025, 4:00 PM EDT - 1 year ago

Atea Pharmaceuticals Quarterly report: Q1 2025


Atea Pharmaceuticals Earnings release: Q1 2025

May 12, 2025, 4:00 PM EDT - 1 year ago

Atea Pharmaceuticals Earnings release: Q1 2025


Atea Pharmaceuticals to host hepatitis C virus KOL panel

2025-05-01T11:36:00.000Z - 1 year ago

Atea Pharmaceuticals to host hepatitis C virus KOL panel


Atea Pharmaceuticals Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Atea Pharmaceuticals Proxy statement: Proxy Filing


Atea Pharmaceuticals Proxy statement: Proxy Filing

Apr 3, 2025, 8:00 AM EDT - 1 year ago

Atea Pharmaceuticals Proxy statement: Proxy Filing


Atea Pharmaceuticals Proxy statement: Proxy Filing

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Atea Pharmaceuticals Proxy statement: Proxy Filing


Atea Pharmaceuticals Proxy statement: Proxy Filing

Mar 26, 2025, 8:00 AM EDT - 1 year ago

Atea Pharmaceuticals Proxy statement: Proxy Filing


Atea Pharmaceuticals Proxy statement: Proxy Filing

Mar 24, 2025, 8:00 AM EDT - 1 year ago

Atea Pharmaceuticals Proxy statement: Proxy Filing


Atea Pharmaceuticals reports Q4 EPS (40c), consensus (29c)

2025-03-06T21:36:49.000Z - 1 year ago

Atea Pharmaceuticals reports Q4 EPS (40c), consensus (29c)


Atea Pharmaceuticals Earnings Call Transcript: Q4 2024

Mar 6, 2025, 4:30 PM EST - 1 year ago

Atea Pharmaceuticals Earnings Call Transcript: Q4 2024


Atea Pharmaceuticals Annual report: Q4 2024

Mar 6, 2025, 4:30 PM EST - 1 year ago

Atea Pharmaceuticals Annual report: Q4 2024


Atea Pharmaceuticals Earnings release: Q4 2024

Mar 6, 2025, 4:30 PM EST - 1 year ago

Atea Pharmaceuticals Earnings release: Q4 2024


Atea Pharmaceuticals Slides: Q4 2024

Mar 6, 2025, 4:30 PM EST - 1 year ago

Atea Pharmaceuticals Slides: Q4 2024


Atea Pharmaceuticals Slides: FY 2025

Jan 15, 2025, 8:15 PM EST - 1 year ago

Atea Pharmaceuticals Slides: FY 2025


Atea Pharmaceuticals Earnings Call Transcript: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

Atea Pharmaceuticals Earnings Call Transcript: Q3 2024


Atea Pharmaceuticals Quarterly report: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

Atea Pharmaceuticals Quarterly report: Q3 2024


Atea Pharmaceuticals Earnings release: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

Atea Pharmaceuticals Earnings release: Q3 2024


Atea Pharmaceuticals Slides: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

Atea Pharmaceuticals Slides: Q3 2024


Atea Pharmaceuticals Earnings Call Transcript: Q2 2024

Aug 7, 2024, 4:30 PM EDT - 2 years ago

Atea Pharmaceuticals Earnings Call Transcript: Q2 2024


Atea Pharmaceuticals Quarterly report: Q2 2024

Aug 7, 2024, 4:30 PM EDT - 2 years ago

Atea Pharmaceuticals Quarterly report: Q2 2024


Atea Pharmaceuticals Earnings release: Q2 2024

Aug 7, 2024, 4:30 PM EDT - 2 years ago

Atea Pharmaceuticals Earnings release: Q2 2024


Atea Pharmaceuticals Slides: Q2 2024

Aug 7, 2024, 4:30 PM EDT - 2 years ago

Atea Pharmaceuticals Slides: Q2 2024


Atea Pharmaceuticals Proxy statement: Proxy Filing

Jun 4, 2024, 8:00 AM EDT - 2 years ago

Atea Pharmaceuticals Proxy statement: Proxy Filing


Atea Pharmaceuticals Earnings Call Transcript: Q1 2024

May 14, 2024, 4:30 PM EDT - 2 years ago

Atea Pharmaceuticals Earnings Call Transcript: Q1 2024


Atea Pharmaceuticals Quarterly report: Q1 2024

May 14, 2024, 4:30 PM EDT - 2 years ago

Atea Pharmaceuticals Quarterly report: Q1 2024


Atea Pharmaceuticals Earnings release: Q1 2024

May 14, 2024, 4:30 PM EDT - 2 years ago

Atea Pharmaceuticals Earnings release: Q1 2024


Atea Pharmaceuticals Slides: Q1 2024

May 14, 2024, 4:30 PM EDT - 2 years ago

Atea Pharmaceuticals Slides: Q1 2024


Atea Pharmaceuticals Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Atea Pharmaceuticals Proxy statement: Proxy Filing


Atea Pharmaceuticals Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Atea Pharmaceuticals Proxy statement: Proxy Filing


Atea Pharmaceuticals Earnings Call Transcript: Q4 2023

Feb 28, 2024, 4:30 PM EST - 2 years ago

Atea Pharmaceuticals Earnings Call Transcript: Q4 2023


Atea Pharmaceuticals Annual report: Q4 2023

Feb 28, 2024, 4:30 PM EST - 2 years ago

Atea Pharmaceuticals Annual report: Q4 2023


Atea Pharmaceuticals Earnings release: Q4 2023

Feb 28, 2024, 4:30 PM EST - 2 years ago

Atea Pharmaceuticals Earnings release: Q4 2023


Atea Pharmaceuticals Slides: Q4 2023

Feb 28, 2024, 4:30 PM EST - 2 years ago

Atea Pharmaceuticals Slides: Q4 2023


DARKP00L
DARKP00L May. 27 at 11:11 AM
$AVIR 07:09 on May. 27 2026 Atea Pharmaceuticals' BEM/RZR Phase 1 Results Show Low Drug-Drug Interaction Risk With Commonly Used Medications For Hepatitis C Patients #tradeideas
0 · Reply
OnlyFibs
OnlyFibs May. 23 at 4:29 PM
Is $AVIR the ultimate binary value play? 🚀 Revenue is non-existent as they fund Phase 3 trials, but the $256M cash pile provides enough runway to get to the 2026 data milestones without dilution. The market is skeptical, but the HCV market is massive. This is a pure clinical-outcome trade—either you believe the data, or you don't. 💎 🐂 Bulls: Look for a sustained close over 4.80 to validate the breakout and trigger the next leg 🐻 Bears: Watch 3.60 for a support test; failure here confirms the bearish trend #avir #Investing #Biotech #hovdid
0 · Reply
rao4
rao4 May. 18 at 9:44 PM
$AVIR why can't just merck take the initiative and buy the company, they have licensed ruzasvir already. Probability of phase 3 hcv being successful is very high if they showed good results in phase 2.
0 · Reply
laaarsas
laaarsas May. 15 at 3:45 PM
$AVIR Ok srsly data leak or what?
0 · Reply
laaarsas
laaarsas May. 14 at 9:52 PM
$AVIR So why is it actually down?
0 · Reply
Following_the_trend
Following_the_trend May. 14 at 2:09 PM
$AVIR Probably should have timed my entry better (3 day rule). Just a starter so no big deal. GL everyone.
0 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor May. 13 at 3:21 PM
$AVIR why the dip today?
1 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor May. 13 at 3:03 PM
$AVIR why the drop today?
0 · Reply
laaarsas
laaarsas May. 13 at 2:41 PM
$AVIR why down today? Unclear to me
1 · Reply
Following_the_trend
Following_the_trend May. 13 at 2:24 PM
$AVIR Ok, finally a starter here.
0 · Reply
focafoca99
focafoca99 May. 13 at 11:28 AM
$AVIR showcases three abstracts accepted for presentation at EASL 2026.
0 · Reply
Olivia_Strickland
Olivia_Strickland May. 12 at 10:21 PM
$AVIR down 5.27% AH after a Q1 print that technically beat by 2 cents, because apparently a 2-cent beat on a 57-cent loss is the new sell signal. session vol nothing special at 1.19x avg and the YTD is still +58% so the chart isn't broken, just the AH crowd doing AH crowd things at $5.20. dry take, this fills the red candle by mid-morning once someone actually pulls up the deck. anyone else think the post-earnings fade on small biotechs has become its own setup, or am I reading too much into a $440M cap moving on 309k shares? live AH tape + alerts: https://tapeboard.com/chart/AVIR?utm_source=stocktwits&utm_medium=post&utm_campaign=olivia&utm_content=avir-ah-dn-tape
0 · Reply
MarketBeat
MarketBeat May. 12 at 10:08 PM
https://marketbeat.com/a/8651109/ $AVIR Atea Pharmaceuticals Q1 Earnings Call Highlights
0 · Reply
EarningsInsider
EarningsInsider May. 12 at 9:32 PM
https://www.marketbeat.com/earnings/reports/2026-5-12-atea-pharmaceuticals-inc-stock/ $AVIR Atea Pharmaceuticals Earnings Transcript
0 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 12 at 9:29 PM
$AVIR Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.57 down -42.50% YoY • Atea Pharmaceuticals Inc expects to report topline results for its C-BEYOND HCV trial in mid-2026 and C-FORWARD at year-end 2026, targeting March 2027 for NDA submission, with AT-587 entering Phase 1 in mid-2026.
0 · Reply
Cutlass
Cutlass May. 12 at 8:59 PM
$AVIR Two's are gone - 😒
1 · Reply
Cutlass
Cutlass May. 12 at 8:36 PM
$AVIR Plenty of cash ✍️👀📣
0 · Reply
focafoca99
focafoca99 May. 12 at 8:29 PM
$AVIR released its Q1 2026 financial results in a press release attached to the 8‑K.
0 · Reply
Cutlass
Cutlass May. 12 at 8:07 PM
$AVIR The global Phase 3 program consists of two open-label, controlled trials: C-BEYOND (conducted in North America): Enrollment completed in December 2025 with more than 880 patients; topline results expected mid-2026. C-FORWARD (conducted outside North America): Enrollment on track for completion mid-2026; topline results expected around year-end 2026.
0 · Reply
BillionerOfKing
BillionerOfKing May. 1 at 10:21 AM
$AVIR Current Stock Price: $5.51 Contracts to trade: $5.0 AVIR May 15 2026 Call Entry: $0.91 Exit: $1.70 ROI: 87% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
laaarsas
laaarsas Apr. 11 at 3:45 PM
$AVIR if ph3 hits what share price will we see?
1 · Reply
laaarsas
laaarsas Apr. 9 at 2:12 PM
$AVIR so what do ppl expect here?
0 · Reply